Verrica Pharmaceuticals EBITDA vs. Gross Profit
| VRCA Stock | USD 0.87 0.01 1.14% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -62.2 M | Current Value -59.1 M | Quarterly Volatility 21.4 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.0 | 0.8544 |
|
|
For Verrica Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Verrica Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Verrica Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Verrica Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Verrica Pharmaceuticals over time as well as its relative position and ranking within its peers.
Verrica |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.198 | Quarterly Revenue Growth 27.445 | Return On Assets (0.71) | Return On Equity (20.60) |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Verrica Pharmaceuticals Gross Profit vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Verrica Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Verrica Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Verrica Pharmaceuticals is rated below average in ebitda category among its peers. It is rated below average in gross profit category among its peers . At present, Verrica Pharmaceuticals' EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Verrica Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Verrica Gross Profit vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Verrica Pharmaceuticals |
| = | (62.2 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Verrica Pharmaceuticals |
| = | 8.31 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Verrica Gross Profit Comparison
Verrica Pharmaceuticals is currently under evaluation in gross profit category among its peers.
Verrica Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Verrica Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Verrica Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Verrica Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Verrica Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 577 K | 605.9 K | |
| Operating Income | -65.8 M | -62.5 M | |
| Net Loss | -48.3 M | -45.9 M | |
| Income Before Tax | -67 M | -63.6 M | |
| Total Other Income Expense Net | -1.2 M | -1.3 M | |
| Net Loss | -22 M | -23.1 M | |
| Net Loss | -67 M | -63.6 M | |
| Income Tax Expense | 668.1 K | 634.7 K | |
| Interest Income | 2.2 M | 2.3 M | |
| Non Operating Income Net Other | -917.1 K | -871.2 K | |
| Change To Netincome | 7.8 M | 4.8 M | |
| Net Loss | (1.48) | (1.55) | |
| Income Quality | 0.58 | 0.90 | |
| Net Income Per E B T | 1.02 | 0.86 |
Verrica Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Verrica Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Verrica Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Verrica Pharmaceuticals' important profitability drivers and their relationship over time.
Use Verrica Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Verrica Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Verrica Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Verrica Pharmaceuticals Pair Trading
Verrica Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Verrica Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Verrica Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Verrica Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Verrica Pharmaceuticals to buy it.
The correlation of Verrica Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Verrica Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Verrica Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Verrica Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Verrica Pharmaceuticals position
In addition to having Verrica Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Software Thematic Idea Now
Software
Companies that develop and distribute software and software systems to individuals or business. The Software theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Software Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
To fully project Verrica Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Verrica Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Verrica Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.